This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Hemera Biosciences
Sponsor:
Information provided by (Responsible Party):
Hemera Biosciences
ClinicalTrials.gov Identifier:
NCT03144999
First received: May 2, 2017
Last updated: May 16, 2017
Last verified: May 2017
May 2, 2017
May 16, 2017
March 29, 2017
October 31, 2017   (Final data collection date for primary outcome measure)
Number of participants experiencing ocular and systemic adverse events as graded by CTCAE v4.0 [ Time Frame: 26 Weeks ]
Measure intraocular inflammation, ocular changes and systemic side effects following a single intraocular injection of AAVCAGsCD59
Same as current
Complete list of historical versions of study NCT03144999 on ClinicalTrials.gov Archive Site
  • Evaluate the change in area of GA in eyes with dry AMD [ Time Frame: 26 Weeks ]
    Efficacy of AAVCAGsCD59
  • Evaluate the rate of growth of GA in eyes with dry AMD [ Time Frame: 26 Weeks ]
    Efficacy of AAVCAGsCD59
  • Incidence of conversion of dry AMD to wet AMD [ Time Frame: 26 Weeks ]
    Efficacy of AAVCAGsCD59
  • Change in drusen volume measured by spectral domain OCT [ Time Frame: 26 Weeks ]
    Efficacy of AAVCAGsCD59
  • Prevention of loss of 15 or more letters on an ETDRS visual acuity chart [ Time Frame: 26 Weeks ]
    Efficacy of AAVCAGsCD59
Same as current
Not Provided
Not Provided
 
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAVCAGsCD59 in Patients With Advanced Non-Exudative (Dry) Age-Related Macular Degeneration With Geographic Atrophy

Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over age 60. AMD is classified as wet and dry. Wet AMD constitutes 10 to 15% of all cases of AMD and occurs when an abnormal blood vessel grows in or under the retina leading to central vision loss. Wet AMD is successfully treated with injections in the eye on a monthly basis that stop the blood vessel from growing and leaking. The most common form of AMD is the dry variant or dry AMD that affects 85 to 90% of all patients with AMD. In dry AMD, there is loss of retinal pigment, formation of deposits called drusen, and loss of the vessels in a layer of the retina called the choriocapillaris. In the most severe forms of dry AMD there is loss of retinal tissue called geographic atrophy. Over time retinal tissue degenerates in the area responsible for central vision leading to vision loss leading to legal blindness. Currently no treatment for dry AMD exists so that there is a significant unmet need in patients with this ocular disease.

Recently, evidence has implicated an overactive inflammatory cascade called the complement system as playing a pivotal role in the development of dry AMD. The complement cascade consists of 3 arms that converge to form a pore-like complex on the surface of cells called the membrane attack complex (MAC). Accumulation of MAC on cell surfaces leads to cell damage and death causing the clinical findings seen in AMD. Normal cells within the human body produce a protein on their cell surfaces called CD59 that blocks the MAC from forming. In AMD, the complement cascade is upregulated and leads to more MAC formation than the body can protect itself against leading to cell destruction.

AAVCAGsCD59, an ocular gene therapy product that is injected in to the eye in the physician's office, causes normal retinal cells to increase the expression of a soluble form of CD59 (sCD59). This soluble recombinant version of the naturally occurring CD59 is designed and intended to protect retinal cells that are responsible for central vision by inhibiting the formation of the membrane attack complex (MAC), the terminal step of complement-mediated cell lysis. In gene therapy the cells of the retina are potentially permanently altered to make sCD59 for the life of the patient. With gene therapy only one injection is needed for the drug to be effective for the patient's entire life. This study will evaluate the safety after a single injection of AAVCAGsCD59 administered in an office setting for patients whose enrolled eye has advanced dry AMD with geographic atrophy. The initial study is 26 weeks followed by an additional 18-month safety evaluation.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
This is a dose escalation study consisting of a low, mid, and high dose to evaluate the maximum tolerated dose (MTD).
Masking: None (Open Label)
Primary Purpose: Other
Dry Age-related Macular Degeneration
Biological: AAVCAGsCD59
AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
Other Name: HMR59
  • Experimental: Low Dose
    AAVCAGsCD59
    Intervention: Biological: AAVCAGsCD59
  • Experimental: Mid Dose
    AAVCAGsCD59
    Intervention: Biological: AAVCAGsCD59
  • Experimental: High Dose
    AAVCAGsCD59
    Intervention: Biological: AAVCAGsCD59
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
25
October 31, 2019
October 31, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men or women 50 years of age or older
  • Advanced dry AMD with GA in the study eye
  • BCVA Snellen equivalent of 20/80 or worse in the study eye using ETDRS charts at a starting distance of 4m after the first 3 patients are enrolled and demonstrate favorable safety data
  • Total GA lesion size 5mm2 (2 DA) to 20mm2 (8 DA) in the study eye; if multifocal, then at least one focus of GA needs to measure 1.27 mm2 (0.5 DA)
  • Fellow eye BCVA of 20/800 or better and must be the eye with the better visual acuity
  • Must be willing to undergo paracentesis of the anterior chamber

Exclusion Criteria:

  • GA secondary to non AMD etiologies
  • Prior or active choroidal neovascularization (CNV) in the study eye
  • History of conditions in the study eye during screening which might alter visual acuity or interfere with study testing
  • Active uncontrolled glaucoma
  • Intraocular surgery in the study eye within 3 months of enrollment or are known or likely candidate for intraocular surgery (including cataract surgery) in the study eye within 1 year of treatment
  • Acute or chronic infection in the study eye
  • History of inflammation in the study eye or ongoing inflammation in either eye
  • History of uveitis in the study eye
  • Ongoing ocular inflammation in either eye
  • Any contraindication to intravitreal injection
  • Currently using or have used treatment for exudative AMD in the study eye only: laser photocoagulation, photodynamic therapy (PDT), ranibizumab (Lucentis®), pegaptanib sodium (Macugen®), bevacizumab (Avastin®) or aflibercept (Eylea®)
  • Currently using any periocular (study eye), intravitreal (study eye) or systemic (oral or intravenous) corticosteroids within 3 months prior to screening.
  • Any of the following underlying systemic diseases:

    • Unstable or severe cardiovascular disease, e.g., congestive heart failure (New York Heart Association Functional class III or IV), myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina, or critical limb ischemia;
    • Poorly controlled diabetes;
    • Clinically significant impaired renal or hepatic function, for example:
    • Cerebrovascular disease within 12 months prior to Screening;
    • Dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease);
    • Have a malignancy at Screening or a history of malignancy that precludes completion of this 2-year study, including presence of tumor or disease whose treatment may directly affect the ability to evaluate the safety and efficacy of AAVCAGsCD59, or currently undergoing treatment for a specific cancer;
    • Immunocompromised conditions and/or need for immunosuppressive therapy;
  • Any significant poorly controlled illness that would preclude study compliance and follow-up
  • Current or prior use of any medication known to be toxic to the retina or optic nerve including, but not limited, to chloroquine/hydrochloroquine, deferoxamine, phenothiazines and ethambutol
  • Previous treatment with any ocular or systemic gene transfer product
  • Received any investigational product within 120 days prior to screening
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
No
Contact: Sandy Chong 617-314-2627 schong@eyeboston.com
United States
 
 
NCT03144999
HMR-1001
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Hemera Biosciences
Hemera Biosciences
Not Provided
Principal Investigator: Jeff Heier, MD Ophthalmic Consultants of Boston
Hemera Biosciences
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP